Search filters

Filters
Clear All

Phase

  • 1
  • 5
  • 2
  • 15
  • 23
  • 8
  • 2
  • 21

Found 23 lancaster-general-health trials

A listing of lancaster-general-health medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Sort by:
UPCC 17925/28925 Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers
18 years or above
All genders
Observational
This study investigates solid tumors. Participants will provide clinical data and biological samples to support cancer biomarker research.The focus of this study is to evaluate the development of tests for cancer detection and assessing the risk of cancer recurrence.Who can participate: Adults aged 18 and older with a confirmed diagnosis …
Test Trial for Go-Live 1 - V7.3 smoketesting
55 years - 100 years
All genders
Test Trial for Go-Live for data migration - testExclusion Criteria:The presence of any active, known, or suspected autoimmune disease. Type 1 diabetes, which was admitted to receive stable dose of insulin, hypothyroidism, which required only hormone replacement therapy, skin disease with no need to systemic treatment and no acute exacerbation …
S2302 - Comparing two treatments for advanced lung cancer: one without chemotherapy (using a combination of drugs called ramucirumab and pembrolizumab), and the other following the usual care after immunotherapy
All genders
Phase 3
This study compares the impact of using a combination of drugs, ramucirumab and pembrolizumab, versus standard chemotherapy for treating advanced non-small cell lung cancer that is stage IV or recurrent. Ramucirumab blocks new blood vessel growth that tumors need, while pembrolizumab boosts the immune system to fight cancer. The trial …
CCTG MA.39: Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer
35 years or above
Female
This study will compare the good and bad effects of not giving regional radiotherapy versus using regional radiotherapy in patients with low risk breast cancer as indicated by Oncotype DX Recurrence Score. This is intended to help researchers discover if not giving regional radiotherapy will be as beneficial as using …
A Randomized, Open-Label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
18 years - 100 years
Female
Phase 3
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer …
Janssen MajesTEC-9
100 years or below
All genders
Phase 3
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in multiple myeloma patients.
ASCEND CSP
18 years - 99 years
All genders
This is a prospective, multi-center, global, single-arm, pivotal investigational study designed to evaluate the safety and effectiveness of the CSP ICD Lead in a subject population indicated for ICD or CRT-D therapy. 
BOLT
99 years or below
All genders
The objective of this study is to demonstrate the safety and efficacy of the Indigo Aspiration system for percutaneous mechanical thrombectomy in a population presenting with obstruction due to deep vein thrombosis (DVT) who are eligible for treatment.
HORIZON OLE
99 years or below
All genders
Phase 3
This is an open-label, single arm, multicenter extension study for participants with established CVD and elevated Lp(a) who completed the parent study. The purpose of this study is to assess the long-term safety and tolerability of pelacarsen (TQJ230). The study consists of: Screening period (up to approximately 30 days) and …
HF-POLARIS
18 years - 99 years
All genders
Phase 3
This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. 
1 - 10 of 23